首页> 外国专利> 1,2,3,4,5,6-HEXAHYDRO-8-HYDROXY-3-BENZAZOCINE DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

1,2,3,4,5,6-HEXAHYDRO-8-HYDROXY-3-BENZAZOCINE DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

机译:1,2,3,4,5,6-己基-8-羟基-3-苯甲嗪衍生物,它们的制备和药物成分

摘要

1448243 1,2,3,4,5,6 - Hexahydro - 8 - hydroxy-benzazocines F HOFFMANN-LA ROCHE & CO AG 23 Oct 1973 [24 Oct 1972 6 April 1973 27 July 1973] 49201/73 Heading C2C Novel 1,2,3,4,5,6 - hexahydro - 8 - hydroxybenzazocines of the general formula wherein R 2 is a C 1-7 alkyl, C 3-7 cycloalkyl-C 1-7 alkyl, C 2-7 alkenyl, C 3-7 alkynyl or aryl-C 1-7 alkyl group and each of R 3 and R 4 is a hydrogen atom or C 1-7 alkyl group, at least one of R 3 and R 4 being a C 1-7 alkyl group and at least one of R 2 , R 3 and R 4 being other than a methyl group (present as racemates or optical antipodes when R 3 and R 4 are not alike), and pharmaceutically acceptable acid addition salts thereof are prepared (a) by reacting a 1,2,3,4,5,6-hexahydro-8- alkoxy - benzazocine of the general formula wherein R 1 is a C 1-7, alkyl group, or an acid addition salt thereof with an ether-cleaving agent; or (b) by reacting the corresponding compound in which R 2 is a hydrogen atom or an acid addition salt thereof with agents yielding the group R 2 e.g. an acylating agent, which gives an N-acyl- 8-acyloxybenzazocine, followed by a reducing agent; followed optionally by separation of a resulting reacemate into the optical antipodes and by conversion of a resulting base into a pharmaceutically acceptable acid addition salt. 1,2,3,4,5,6 - Hexahydro - 8 - alkoxy - benzazocines of the general formula II are prepared by alkylating, alkenylating or alkynylating the corresponding compound in which R 2 is a hydrogen atom and 1,2,3,4,5,6-hexahydro-8- hydroxy - benzazocines of the general Formula I wherein R 2 is a hydrogen atom are prepared from the same starting materials by treatment with an ether-cleaving agent. 1,2,3,4,5,6 - Hexahydro - 8 - alkoxy - benzazocines of the general Formula II wherein R 2 is a hydrogen atom are prepared (i) by condensing an amino acid of the general formula and reducing the resulting lactam of the general formula or (ii) by benzylating the amino acid (16), condensing the resulting N-benzyl-amino acid, reducing the resulting lactam and removing the benzyl group from the resulting N-benzylbenzazocine by hydrogenolysis. Amino acids (16) are prepared by reacting a p-R 1 O-benzaldehyde with CH 3 COCHR 3 R 4 , reducing the resulting ketone of the general formula heating the resulting alcohol of the general formula under acidic conditions, oxidizing the resulting tetrahydronaphthalene of the general formula nitrosating the resulting naphthalenone (characterized as the 2,4-dinitrophenylhydrazone) of the general formula ring-opening the resulting oxime of the general formula reducing the resulting nitrile of the general formula to give an amino acid and then an amino alcohol of the respective general formulµ introducing an acetyl group R 5 and a phthaloyl group R 6 into the amino alcohol, chlorinating the resulting acetate of the general formula reacting the resulting chloride of the general formula with an alkali metal cyanide, and removing the phthaloyl group from and hydrolysing the resulting cyanide of the general formula Pharmaceutical compositions having analgesic activity comprise, as active ingredient, a 1,2,3,4,5,6 hexahydro - 8 - hydroxy - benzazocine of the general Formula I or a pharmaceutically acceptable acid addition salt thereof, in association with compatible pharmaceutical carrier suitable for parenteral or enteral administration.
机译:1448243 1,2,3,4,5,6-六氢-8-羟基苯甲佐星F HOFFMANN-LA ROCHE&CO AG 1973年10月23日[1972年10月24日1973年4月6日1973年7月27日] 49201/73标题C2C小说1,具有通式的2,3,4,5,6-六氢-8-羟基苯甲唑啉星,其中R 2是C 1-7烷基,C 3-7环烷基-C 1-7烷基,C 2-7烯基,C 3 -7炔基或芳基-C 1-7烷基,且R 3和R 4各自为氢原子或C 1-7烷基,R 3和R 4中的至少一个为C 1-7烷基, R 2,R 3和R 4中的至少一个不是甲基(当R 3和R 4不同时作为外消旋体或旋光对映体存在),其药学上可接受的酸加成盐是通过(a)通式为1,2,3,4,5,6-六氢-8-烷氧基-苯并恶嗪的化合物,其中R 1为C 1-7烷基,或其与醚裂解剂的酸加成盐; (b)使R 2为氢原子的相应化合物或其酸加成盐与产生基团R 2的试剂反应,如酰化剂,其产生N-酰基-8-酰氧基苯甲佐辛,然后是还原剂;然后任选地将所得的醋酸酯分离成旋光对映体,以及将所得的碱转化成药学上可接受的酸加成盐。通式Ⅱ的1,2,3,4,5,6-六氢-8-烷氧基-苯并恶嗪是通过烷基化,烯基化或炔化其中R 2为氢原子且1,2,3,通式I的4,5,6-六氢-8-羟基-苯甲恶嗪(其中R 2是氢原子)是由相同的原料通过用醚裂解剂处理而制备的。通式(Ⅱ)中R 2为氢原子的1,2,3,4,5,6-六氢-8-烷氧基-苯并恶嗪是通过(i)缩合通式的氨基酸并还原所得内酰胺制备的。通式或(ii)的通式(ii)是通过将氨基酸(16)苄基化,缩合所得的N-苄基氨基酸,还原所得的内酰胺,并通过氢解从所得的N-苄基苯甲唑啉中除去苄基。通过使pR 1 O-苯甲醛与CH 3 COCHR 3 R 4反应,还原得到的通式的酮,在酸性条件下加热得到的通式的醇,将得到的通式的四氢萘氧化,来制备氨基酸(16)。通式的亚硝化所得的萘萘酮(特征为2,4-二硝基苯基hydr),使通式的所得肟开环,还原通式的所得腈,得到相应的氨基酸,然后是氨基醇一般的配方是将乙酰基R 5和邻苯二甲酰基R 6引入氨基醇中,氯化得到的通式的乙酸盐,使得到的通式的氯化物与碱金属氰化物反应,从中除去邻苯二甲酰基并进行水解。所得通式为氰化物的具有止痛活性的药物组合物包含活性成分术语I,是通式I的1,2,3,4,5,6六氢-8-羟基-苯甲唑啉或其药学上可接受的酸加成盐,与适合于肠胃外或肠内给药的相容性药物载体结合。

著录项

  • 公开/公告号IL43456A

    专利类型

  • 公开/公告日1976-12-31

    原文格式PDF

  • 申请/专利权人 SPARAMEDICA AG;

    申请/专利号IL19730043456

  • 发明设计人

    申请日1973-10-22

  • 分类号A61K27/00;C07D41/00;

  • 国家 IL

  • 入库时间 2022-08-23 00:51:52

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号